Telix Pharmaceuticals Ltd — Capital/Financing Update 2018

Aug 2, 2018

==> picture [143 x 79] intentionally omitted <==

Telix Pharmaceuticals Limited Receives $55m Overseas Finding From Innovation and Science Australia

Melbourne (Australia) – 3[rd] August 2018 . Telix Pharmaceuticals Limited (ASX.TLX) (“ Telix ”, the “ Company ”), an Australian biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (“ MTR ”), has today announced that it has it has been granted certificates from the Department of Innovation, Industry and Science (“ Innovation and Science Australia ”) for an advance/overseas R&D tax finding totaling AUD $55.2 million.

The certificates, issued under s28a and s28c under the Industry Research and Development Act 1986 (“ IR&D Act ”), pertain to highly specific works of pre-clinical, clinical, manufacturing and regulatory-related activity undertaken internationally by Telix in relation to its diagnostic and therapeutic oncology programs in kidney cancer (TLX250), prostate cancer (TLX591) and glioblastoma (TLX101). The certificates are issued to enable partial recovery of overseas R&D expenditure that are essential to Telix’s programs but cannot be executed domestically by Australian vendors and service providers.

Telix Group Chief Financial Officer, Mr Douglas Cubbin stated, “This overseas finding from Innovation and Science Australia reflects over a year of effort and extensive documentation evidencing the robustness and validity of our product development programs. The impact of this finding is AUD $55.2 million over 5 years with a likely impact of approximately AUD $8-10m in the current financial year. As such, this represents an important source of additional non-dilutive funding for the Company.”

Telix Group Managing Director and CEO, Dr. Christian Behrenbruch added, “We are grateful for the consideration given to the Company by Innovation and Science Australia and value the financial impact this award will have on our cancer programs. Along with the AUD $50m raised in our highly successful public offering in November last year, Telix is positioned to deliver signifiant clinical and financial outcomes to patients, shareholders and the Australian tax-payer.”

Telix endeavours to use Australian vendors and clinical service providers wherever possible. Due to the advanced nature of Telix’s clinical programs, it is often necessary to conduct research, manufacturing and clinical activities in international jurisdictions, including from vendors and service provider that are authorized to perform activities under highly specialized and regulated conditions. Telix Group (including international subsidiaries) financial year ends December 31[st] .

About Telix Pharmaceuticals Limited

Telix Pharmaceuticals Limited (Telix) is a global biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR). The company is headquartered in Melbourne with international operations in Brussels (EU), Kyoto (JP) and Indianapolis (US). Telix is developing a portfolio of clinical-stage oncology products that address significant unmet medical need in renal, prostate and brain (glioblastoma) cancer. Telix is listed on the Australian Securities Exchange (ASX:TLX). For more information visit www.telixpharma.com.

Page 1

==> picture [143 x 79] intentionally omitted <==

Telix Corporate Contact

Telix Investor Relations (Australia)

Dr Christian Behrenbruch Kyahn Williamson Telix Pharmaceuticals Limited WE Buchan CEO Tel: +61 (3) 9866 4722 Email: chris@telixpharma.com Email: kwilliamson@buchanwe.com.au

Telix Investor Relations (US)

Lisa Wilson In-Site Communications Tel: +1 212 452 2793 Email: lwilson@insitecony.com

Important Information

This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933 (the “US Securities Act”), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold within the United States, unless the securities have been registered under the US Securities Act or an exemption from the registration requirements of the US Securities Act is available.

None of the products referred to in this release have obtained a marketing authorization from any regulatory body, in any jurisdiction.

Page 2